Abstract: This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and with the reduction of skin irritation that often accompanies transdermal and topical drug delivery.

Abstract: The present invention provides methods for treating a variety of urogenital disorders, such as, for example, vaginismus, dyspareunia, vulvodynia (including vulvar vestibulitis), interstitial cystitis, nonspecific urethriris (i.e., nonspecific pain and/or burning of the urinary tract) and sexual dysfunctions, such as, for example, female sexual arousal disorders and female sexual orgasmic disorders, using a variety of compounds, including, but not limited to, NO donors, calcium channel blockers, cholinergic modulators, ?-adrenergic receptor antagonists, ?-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators (e.g.

Abstract: Semisolid topical pharmaceutical compositions comprising a therapeutically effective amount of a mammalian hormone and an effective amount of a penetration enhancer and methods for their use are provided. The pharmaceutical compositions and methods for their use can provide blood or plasma levels of the administered hormone within a predetermined or normal range of hormone values. In particular embodiments, the hormone is testosterone or estrogen and the amount to be applied to the skin of the subject is determined according to the weight or body mass index of the subject. The topical composition can be formulated in solutions, creams, lotions, ointments, and gels.

Abstract: This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and with the reduction of skin irritation that often accompanies transdermal and topical drug delivery.

Abstract: This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and with the reduction of skin irritation that often accompanies transdermal and topical drug delivery.

Abstract: The present invention provides methods for treating a variety of urogenital disorders, such as, for example, vaginismus, dyspareunia, vulvodynia (including vulvar vestibulitis), interstitial cystitis, nonspecific urethriris (i.e., nonspecific pain and/or burning of the urinary tract) and sexual dysfunctions, such as, for example, female sexual arousal disorders and female sexual orgasmic disorders, using a variety of compounds, including, but not limited to, NO donors, calcium channel blockers, cholinergic modulators, &agr;-adrenergic receptor antagonists, &bgr;-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators (e.g.

Abstract: This invention provides concentrated inflammation modifiers obtained from various plant, animal, and mineral sources, and methods for the preparation of such concentrated inflammation modifiers. Also provided are methods of preventing and treating inflammation using the concentrated inflammation modifiers. The invention also provides methods of treating inflammation of the skin and mucosal membranes by administering compositions that contain concentrated inflammation modifiers as active ingredients. The methods are useful for treating inflammatory diseases, as well as for reducing or eliminating inflammation that results from transdermal delivery of a drug, or from cosmetics and skin care products. The concentrated inflammation modifiers and methods are also useful for enhancing wound healing and skin aging.

Abstract: This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and with the reduction of skin irritation that often accompanies transdermal and topical drug delivery.

Abstract: This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and with the reduction of skin irritation that often accompanies transdermal and topical drug delivery.

Abstract: The present invention provides a number of screening methods for evaluating compounds capable of suppressing cytokine production either in vitro or in vivo. The methods generally involve stimulating the production of a cytokine in a cell, exposing a portion of the cells to a putative cytokine modulating agent and determining subsequent levels of cytokine production in the cells. Additionally, the present invention provides certain compounds identified by this method.

Abstract: A diffusion test apparatus (2), used to test diffusion of a drug within a vehicle through a test membrane (8), includes a receiver assembly (6) and a donor assembly (4) secured to one another. The receiver assembly includes a number of open-top receiver receptacles (26) arranged in a chosen pattern along its face (12). Similarly, the donor assembly includes a number of open-top donor receptacles (38) arranged along its face (10) in a mirror image of the chosen pattern. The test membrane is captured between the receiver and donor faces. The drug diffuses through the test membrane and into the receiver liquid (53) during an incubation period (62). Samples (66) of the receiver liquid are preferably automatically transferred to a conventional microtiter plate (70) using a programmed liquid transfer system for assay by a scintillation counter (76).